JAMP-DULOXETINE CAPSULE (DELAYED RELEASE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

DULOXETINE (DULOXETINE HYDROCHLORIDE)

متاح من:

JAMP PHARMA CORPORATION

ATC رمز:

N06AX21

INN (الاسم الدولي):

DULOXETINE

جرعة:

30MG

الشكل الصيدلاني:

CAPSULE (DELAYED RELEASE)

تركيب:

DULOXETINE (DULOXETINE HYDROCHLORIDE) 30MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

15G/50G

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0152350001; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2016-05-02

خصائص المنتج

______________________________________________________________________________
_JAMP-Duloxetine Product Monograph _
_ _
_ _
_ Page 1 of 81 _
PRODUCT MONOGRAPH
PR JAMP-DULOXETINE
Duloxetine Delayed-Release Capsules
Duloxetine (as duloxetine hydrochloride)
30 mg and 60 mg
Manufacturer’s standard
ANALGESIC/ANTIDEPRESSANT/ANXIOLYTIC
Submission Control No: 256492 DATE OF REVISION: September 28, 2021
JAMP Pharma Corporation
1310 rue Nobel
Boucherville,
Québec
J4B 5H3, Canada
______________________________________________________________________________
_JAMP-Duloxetine Product Monograph _
_ _
_ _
_ Page 2 of 81 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT
INFORMATION......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
5
WARNINGS AND PRECAUTIONS
...............................................................................
6
ADVERSE REACTIONS
................................................................................................
18
DRUG INTERACTIONS
................................................................................................
37
DOSAGE AND ADMINISTRATION
............................................................................
40
OVERDOSAGE
..............................................................................................................
43
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 44
STORAGE AND STABILITY
........................................................................................
47
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................ 47
PART II: SCIENTIFIC INFORMATION
..............................................................................
49
PHARMA